Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ASXL3 Gene Mutation	Bainbridge-Ropers syndrome	Active, not recruiting	Phase 1 / Phase 2	2025-09-29		NCT07197268

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
n-Lorem Foundation	18
University of North Carolina, Chapel Hill	249

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University of North Carolina Chapel Hill	Chapel Hill	United States	12

Clinical trials